(Q41537813)

English

Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration

scientific article published on August 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration (English)

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

diffusion-weighted magnetic resonance imaging

1 reference

based on heuristic

inferred from title

author name string

Harriet C Thoeny

1

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

Frederik De Keyzer

2

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

Feng Chen

3

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

Vincent Vandecaveye

4

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

Erik K Verbeken

5

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

Bisan Ahmed

6

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

Xihe Sun

7

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

Yicheng Ni

8

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

Hilde Bosmans

9

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

Robert Hermans

10

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

Allan van Oosterom

11

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

Guy Marchal

12

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

Willy Landuyt

13

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 August 2005

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

7

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

8

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

779-787

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

Vascular-targeting therapies for treatment of malignant disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

Pathology: cancer cells compress intratumour vessels.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

Vascular targeting agents as cancer therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

Diffusion MRI for prediction of response of rectal cancer to chemoradiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

The biology of the combretastatins as tumour vascular targeting agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance imaging and proton spectroscopy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

Osteogenic sarcoma: noninvasive in vivo assessment of tumor necrosis with diffusion-weighted MR imaging

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

Vascular attack as a therapeutic strategy for cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

Diffusion MR imaging: clinical applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

Inhibition of angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

6 June 2018

Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

19 August 2018

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

19 August 2018

Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

19 August 2018

The first international conference on vascular targeting: meeting overview.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

19 August 2018

Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

19 August 2018

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

19 August 2018

Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

19 August 2018

Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1501887

19 August 2018

Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging

1 reference

https://pubmed.ncbi.nlm.nih.gov/16207480

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/16207480

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16207480

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization

1 reference

https://pubmed.ncbi.nlm.nih.gov/16207480

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16207480

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate

1 reference

https://pubmed.ncbi.nlm.nih.gov/16207480

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1593/NEO.04748

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

2 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41537813&oldid=2077084994"